Yadav Birendra Kumar, Shah Ashok Kumar, Karunanand Busi, Sudan Dharampal Singh, Sharma Monika
Department of Biochemistry, Banas Medical College & Research Institute, Palanpur, Gujarat, India.
Department of Biochemistry, Adesh Medical College & Hospital, Shahbad, Haryana, India.
Horm Mol Biol Clin Investig. 2022 Sep 26;44(1):33-37. doi: 10.1515/hmbci-2022-0031. eCollection 2023 Mar 1.
Tuberculosis is an infectious airborne disease caused by . Pulmonary tuberculosis is the ninth most frequent complication of diabetes mellitus. The co-existence of TB and DM in patient causes severe TB symptoms, modify radiological findings, slower response to treatment outcomes and prognosis. IFN-γ is the key cytokine which play role in the protective immune response against mycobacterium infection. The main function of IFN-γ is macrophage activation which is able to exert its microbicidal functions. Estimation and comparison of pre and post treatment serum IFN-γ among pulmonary tuberculosis among diabetic and non-diabetic patients.
The study was conducted in the Departments of Biochemistry and Pulmonary Medicine, FMHS, SGT University, Budhera, Gurugram and District TB Centre, Gurugram, Haryana, India. In this study, 100 newly diagnosed PTB patients without diabetes mellitus and 100 newly diagnosed PTB patients with diabetes mellitus (PTB-DM) above 15 years of age were included after obtaining written consent. 5 mL venous blood was collected from patients of pre and post anti-tubercular treatment. The level of IFN-γ was measured by ELISA method.
The circulating level of IFN-γ in PTB patients was significantly decreased in post-treatment (25.53 ± 6.12 pg/mL) compared to pre-treatment (58.76 ± 16.02 pg/mL) with t-value 32.03 and p-value <0.001. The circulating level of IFN-γ in PTB-DM patients was significantly decreased in post treatment (29.11 ± 7.41 pg/mL) compared to pre-treatment (44.14 ± 10.85 pg/mL) with t-value 31.35 and p-value <0.001. In the present study, level of IFN-γ in pre-treatment PTB patients (58.76 ± 16.02 pg/mL) was significantly raised compared to PTB-DM patients (44.14 ± 10.85 pg/mL) with t-value 7.55 and p-value <0.001. However, level of IFN-γ in post-treatment PTB patients (25.53 ± 6.12 pg/mL) was significantly low compared to PTB-DM patients (29.11 ± 7.41 pg/mL) with t-value 3.71 and p-value <0.001.
The decreased level of IFN-γ in post-treatment compared to pre-treatment in both PTB and PTB-DM patients had shown efficacy of anti-tubercular treatment. However, the post treatment level of IFN-γ was high in PTB-DM patients compared to PTB patients which verified that effect of ATT was low in PTB-DM.
结核病是一种由……引起的空气传播传染病。肺结核是糖尿病第九常见的并发症。患者同时患有结核病和糖尿病会导致严重的结核病症状，改变影像学表现，降低对治疗结果的反应速度和预后。干扰素-γ是在针对分枝杆菌感染的保护性免疫反应中发挥作用的关键细胞因子。干扰素-γ的主要功能是激活巨噬细胞，使其能够发挥杀菌功能。评估和比较糖尿病和非糖尿病肺结核患者治疗前后血清干扰素-γ水平。
本研究在印度哈里亚纳邦古鲁格拉姆布德赫拉SGT大学FMHS生物化学与肺病学系以及古鲁格拉姆地区结核病中心进行。在本研究中，获得书面同意后，纳入了100名新诊断的无糖尿病的肺结核患者和100名新诊断的15岁以上的糖尿病合并肺结核（PTB-DM）患者。在抗结核治疗前后从患者采集5毫升静脉血。采用酶联免疫吸附测定法测量干扰素-γ水平。
肺结核患者治疗后干扰素-γ的循环水平（25.53±6.12 pg/mL）与治疗前（58.76±16.02 pg/mL）相比显著降低，t值为32.03，p值<0.001。糖尿病合并肺结核患者治疗后干扰素-γ的循环水平（29.11±7.41 pg/mL）与治疗前（44.14±10.85 pg/mL）相比显著降低，t值为31.35，p值<0.001。在本研究中，治疗前肺结核患者的干扰素-γ水平（58.76±16.02 pg/mL）与糖尿病合并肺结核患者（44.14±10.85 pg/mL）相比显著升高，t值为7.55，p值<0.001。然而，治疗后肺结核患者的干扰素-γ水平（25.53±6.12 pg/mL）与糖尿病合并肺结核患者（29.11±7.41 pg/mL）相比显著降低，t值为3.71，p值<0.001。
肺结核患者和糖尿病合并肺结核患者治疗后干扰素-γ水平均低于治疗前，这表明了抗结核治疗的疗效。然而，糖尿病合并肺结核患者治疗后的干扰素-γ水平高于肺结核患者，这证实了抗结核治疗在糖尿病合并肺结核患者中的效果较差。
